Detailed summary of study reporting that one in four patients show no symptoms of obstructive sleep apnea after vivos treatment now available on vivos therapeutics website

Highlands ranch, colo., aug. 17, 2021 (globe newswire) -- vivos therapeutics, inc. (the “company” or “vivos”) (nasdaq: vvos), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (osa), today announced a more detailed summary of the national study results announced by the company on july 13, 2021, is now available on the company's website at: https://vivoslife.com/investor-relations/.
VVOS Ratings Summary
VVOS Quant Ranking